Anthrax Vaccine Market: Comprehensive Analysis, Industry Demand, Emerging Trends, and Future Growth Insights

The new report published by The Business Research Company, titled Anthrax Vaccine Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the anthrax vaccine market size has grown steadily in recent years. It will grow from $10.74 billion in 2023 to $11.27 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The anthrax vaccine market size is expected to see strong growth in the next few years. It will grow to $13.80 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15511&type=smp

Rising Infectious Diseases Fueling Growth In The Anthrax Vaccine Market
The rising prevalence of infectious diseases is expected to propel the growth of the anthrax vaccine market going forward. Infectious diseases refer to illnesses caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which can spread directly or indirectly from one person to another, often leading to symptoms ranging from mild to severe and sometimes fatal, depending on the pathogen and the individual's immune response. The prevalence of infectious diseases is due to shifts in the demographics of the world's population, urbanization, changes in the environment and land use, and changes in human behavior. The anthrax vaccine is primarily utilized to protect against anthrax, and its potential for broader use in preventing other infectious diseases is being explored through research into its immunogenic properties and adaptability. For instance, in February 2023, according to the Council on Foreign Relations, a US-based nonprofit organization, up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases had zoonotic origins. Further, worldwide, zoonoses cause 2.7 million human fatalities and 2.5 billion episodes of disease in people each year. Therefore, the rising prevalence of diseases is driving the growth of the anthrax vaccine market.

Advancements And FDA Approvals In The Anthrax Vaccine Market
Major companies operating in the anthrax vaccine market are focused on developing innovative products and getting FDA approvals for their vaccines to ensure safety, efficacy, and availability to those at risk of exposure to anthrax. FDA approval ensures the vaccine is rigorously tested in clinical trials and proven safe for public use. This helps protect individuals from potential adverse effects. For instance, in July 2023, Emergent BioSolutions Inc., a US-based biopharmaceutical company, received approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, from the U.S. Food and Drug Administration (FDA). The approval was predicated on information from a Phase 2 trial evaluating Cyfendus's non-interference with antibacterial medications and Phase 3 clinical research comparing the immunogenicity and safety of the vaccine to BioThrax, the previous anthrax vaccine. Further, developing safer and more effective adjuvants is imperative to address reactogenicity-related problems and enhance the general efficiency of anthrax vaccines.

The anthrax vaccine market covered in this report is segmented -

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine
2) By Application Type: Animal Use, Human Use
3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels

Buy Now & Get Exclusive Discount on this Report, Checkout link @ https://www.thebusinessresearchcompany.com/Discount?id=15511&type=discount

Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc, Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A

Contents of the report:
1. Executive Summary
2. Anthrax Vaccine Market Report Structure
3. Anthrax Vaccine Market Trends And Strategies
4. Anthrax Vaccine Market - Macro Economic Scenario
5. Anthrax Vaccine Market Size And Growth
…..
27. Anthrax Vaccine Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/anthrax-vaccine-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.